Processes for making and using a mesenchymal stem cell derived secretome

1. A method of treatment for an ocular condition in a subject in need thereof comprising administering to the subject a bone marrow-derived mesenchymal stem cell (MSC) secretome composition, wherein the MSC secretome composition comprises: HGF; Pentraxin-3 (TSG-14); VEGF; TIMP-1; Serpin E1; <5 ng/mL IL-8 and a tonicity modifying agent, and wherein the ocular condition is selected from the group consisting of: ocular wound, ocular scarring, ocular neovascularization, increased intraocular pressure, dry eye disease, damaged corneal surface, damaged ocular nerve tissue, retina condition, persistent corneal epithelial defects (PCED), Graft v. Host Disease (GvHD), and Stevens-Johnson Syndrome.

2. The method of treatment according to claim 1 , wherein the tonicity modifying agent is selected from the group consisting of NaCl, KCl, mannitol, dextrose, sucrose, sorbitol, and glycerin.

3. The method of treatment according to claim 1 , wherein the MSC secretome composition further comprises an agent that increases viscosity.

4. The method of treatment according to claim 3 , wherein the adhesive agent is selected from the group consisting of hypromellose, Poloxamer 407, Poloxamer 188, Poloxomer 237, Poloxomer 338, Hypromellose, (HPMC), polycarbophil, polyvinylpyrrolidone (PVP), PVA (polyvinyl alcohol), polyimide, sodium hyaluronate, gellan gum, poly(lactic acid-co-glycolic acid) (PLGA), polysiloxane, polyimide, carboxymethylcellulose (CMC), or hydroxypropyl methylcellulose (HPMC), hydroxy methyl cellulose, hydroxy ethyl cellulose, sodium carboxy methyl cellulose, fibrin glue, polyethyelene glycol, and GelCORE.

5. The method of treatment according to claim 1 , wherein the MSC secretome composition comprises:

i. 0.3-4.5 ng/mL HGF;

ii. 0.5-20 ng/mL Pentraxin-3 (TSG-14);

iii. 100-600 pg/mL VEGF;

iv. 10-200 ng/mL TIMP-1;

v. 20-80 ng/mL Serpin E1; and

vi. <5 ng/mL IL-8.

6. The method of treatment according to claim 1 , wherein the MSC secretome composition further comprises:

i. at least one trophic factors/cytokines selected from the group consisting of TIMP-2, and VEGF-A;

ii. at least one additional factor selected from the group consisting of PEDF (Serpin F1), IGFBP-2, IGFBP-3, SDF-1, Kallikrein 3, MCP-1, Angiogenin, MCP-2, Angio-2, IL-6, IL-17, G-CSF, M-CSF, GM-CSF, IL-8, TNF-beta, and PDGF; and

iii. at least one additional factor selected from the group consisting of DPPIV (dipeptidyl peptidase-4), uPA, Angiopoietin-1, Angiopoietin-2, Amphiregulin, Endostatin, Endothelin-1, Thrombospondin-2, and Thrombospondin-1.

7. The method of treatment according to claim 6 , wherein the MSC secretome composition comprises 1 ng/mL-100 ng/mL of at least one factor selected from the group consisting of Serpin E1, TIMP-1, Thrombospondin-1, Pentraxin-3 (TSG-14), and Serpin F1.

8. The method of treatment according to claim 6 , wherein the MSC secretome composition comprises 400 pg/mL-3000 pg/mL of at least one factor selected from the group consisting of Angiopoietin-1, Angiopoietin-2, Amphiregulin, Endostatin, Endothelin-1, Thrombospondin-2, Thrombospondin-1, Angiogenin, DPPIV, IGFBP-3, and uPA.

9. The method of treatment according to claim 6 , wherein the MSC secretome composition further comprises at least one factor selected from the group consisting of Apolipoprotein A1, Complement Factor D, C-reactive protein, Cystatin C, DKK-1, Emmprin, Osteopontin, vitamin D BP, MIF, RANTES, uPAR, IL-17A, GDF-15, and IFNγ.

10. The method of treatment according to claim 6 , wherein the MSC secretome composition comprises ratios of anti-angiogenic to pro-angiogenic wherein the ratio is >2, >3, >4, or >5.

11. The method of treatment according to claim 6 , wherein the MSC secretome comprises 1 pg/mL-400 pg/mL of VEGF.

12. The method of treatment according to claim 6 , wherein the level of VEGF is 5-10 fold lower than the level of Serpin E1.

13. The method of treatment according to claim 6 , wherein the MSC secretome composition comprises one or more anti-angiogenic factor, and wherein the sum of the concentration of the one or more anti-angiogenic factors relative to the concentration of VEGF is >2, >3, >4, or >5.

14. The MSC secretome composition according to claim 6 , wherein the MSC secretome comprises less than 1000 pg/mL of bFGF, PLGF, and PDGF.

15. The method of treatment according to claim 6 , wherein the MSC secretome composition has a pH of about 4.7 to about 7.5.

16. The method of treatment according to claim 6 , wherein the MSC secretome composition is formulated in a buffer system selected from the group consisting of di/mono sodium phosphate, sodium citrate/citric acid, boric acid/sodium citrate, boric acid/sodium tetraborate, and citric acid/disodium phosphate.

17. The method of treatment according to claim 6 , wherein the MSC secretome composition further comprises mono/di-sodium phosphate, mannitol, and trehalose, and wherein the composition has a pH of about pH 7.4.

18. The method of treatment according to claim 6 , wherein the MSC secretome composition further comprises divalent cations.

19. The method of treatment according to claim 18 , wherein the divalent cations are selected from the group consisting of Mg 2+ , Ca 2+ , and Zn 2+ .

20. The method of treatment according to claim 6 , wherein the MSC secretome composition further comprises di-sodium phosphate/citric acid, mannitol, and trehalose, and wherein the composition has a pH of about pH 6.4.

21. The method of treatment according to claim 6 , wherein the MSC secretome composition does not comprise one or more components selected from the group consisting of: xenobiotic components; Phenol red; peptides and biomolecules <3 kDa; antibiotics; protein aggregates >200 nm; cells; non-exosome/non-Extracellular Vesicles cell debris; hormones; and L-glutamine.

22. The method of treatment according to claim 6 , wherein the MSC secretome composition comprise an anti-angiogenic MSC secretome or an anti-scarring MSC secretome.